Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
The effect of ginseng extract on fatigue in cancer survivors: a randomized double-blind clinical trial.
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Liposomal drug delivery for lung cancer therapy: progress, challenges, and future perspectives.Molecular cancer · 2026Review
- Comprehensive analysis of chloroplast codon usage patterns in the important medicinal genusFrontiers in plant science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeCancer-related fatigue (CRF) is one of the most prevalent and debilitating long-term symptoms among cancer survivors, particularly those with gastrointestinal malignancies. Previous studies on Panax ginseng supplementation have shown inconsistent findings, and evidence in gastrointestinal (GI) cancer survivors remains limited. This study evaluated the efficacy and safety of standardized Panax ginseng extract in reducing CRF. MATERIAL AND
methodsIn this randomized, double-blind, placebo-controlled trial, 65 survivors (≥ 4 months post-treatment) with moderate-to-severe CRF (Brief Fatigue Inventory [BFI] score > 4) were allocated to receive either Panax ginseng extract (250 mg/day) or placebo for four weeks. Fatigue severity (BFI total score) was assessed at baseline and post-intervention. Data analysis was performed with SPSS 27 software, where statistical significance was considered at p < 0.05.Data were analyzed using ANCOVA, controlling for baseline scores. Effect size (Cohen's d) and 95% confidence intervals (CI) were calculated.
resultsAt baseline, mean fatigue scores were similar between groups (Intervention: 5.36 ± 1.18; Placebo: 5.35 ± 1.23). After four weeks, the intervention group demonstrated significant reductions in fatigue (3.99 ± 0.86 vs. 5.37 ± 1.27, p < 0.001), with an adjusted mean difference of - 1.38 (95% CI: - 1.90, - 0.86; Cohen's d = - 1.26). Significant improvements were also observed in general activity, walking ability, mood, and enjoyment of life in the intervention group. No treatment-related adverse events were reported.
conclusionShort-term Panax ginseng supplementation significantly reduced fatigue and improved multiple dimensions of daily functioning in GI cancer survivors, with excellent tolerability. These findings support Panax ginseng as a potential adjunctive intervention for CRF management within supportive care. Larger multicenter studies with extended follow-up are warranted.
Indexed as
Identifiers
41838185What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.